Clinical Trials Logo

Pleural Effusion, Malignant clinical trials

View clinical trials related to Pleural Effusion, Malignant.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06275178 Not yet recruiting - Pleural Effusion Clinical Trials

Medical Thoracoscopy for Diagnosing Unexplained Pleural Effusion: a National Multicenter Retrospective Study

Start date: March 20, 2024
Phase:
Study type: Observational

This study is a national multicenter retrospective study. Patients with unexplained pleural effusion who underwent thoracoscopic or video-assisted thoracoscopic biopsy for patients in recent 10 years were retrospectively collected from multiple centers to understand the proportion and final etiological composition of pleural effusion in China.

NCT ID: NCT05693727 Not yet recruiting - Clinical trials for Pleural Effusion, Malignant

Cancer Ratio,Pleural Fluid Adenosine Deaminase,Lactate Dehydrogenase, interferonY, Tumor Necrosis Factor,and Interleukins{2,12,18}for Differentiation Between Malignant and Non Malignant Pleural Effusion

Start date: September 1, 2023
Phase:
Study type: Observational

To evaluate the ability of cancer ratio and pleural fluid markers to discriminate between malignant and non malignant effusion

NCT ID: NCT05543330 Not yet recruiting - NSCLC Stage IV Clinical Trials

A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC

Start date: September 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1/phase 2, multicenter, open-label study to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of M701 in patients with treatment of malignant pleural effusions caused by NSCLC.

NCT ID: NCT05330065 Not yet recruiting - Clinical trials for Malignant Pleural Effusion

A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion

Start date: August 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Patients with a variety of malignancies can develop malignant pleural effusion (MPE). MPE can cause significant symptoms and result in a marked decrease in quality of life and a poor prognosis. MPE is primarily considered as an immune and vascular manifestation of pleural metastases. The combined use of anti-angiogenic therapy and immunotherapy may be a promising strategy for MPE. This is a Phase Ib/II clinical trial to evaluate the safety and tolerability of administering bevacizumab and camrelizumab into the intrapleural space of subjects with malignant pleural effusion through a pleurX catheter.

NCT ID: NCT04985357 Not yet recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs

Start date: June 2024
Phase:
Study type: Observational

The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from varying cancers and biopsy formats.

NCT ID: NCT04914598 Not yet recruiting - Clinical trials for Malignant Pleural Effusion

A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions

Start date: May 31, 2021
Phase: Phase 3
Study type: Interventional

Malignant Pleural Effusion or Ascites is a common complication of malignant tumor, The objective of this study is to compare the efficacy of Endostar/cisplatin with placebo/cisplatin in patients with malignant pleural effusion or ascites.

NCT ID: NCT04263688 Not yet recruiting - Clinical trials for Non-Small Cell Lung Cancer

Multicenter Observational Study of Advanced Non-small Cell Lung Cancer With Malignant Pleural Effusion

Start date: March 1, 2020
Phase:
Study type: Observational

Multicenter observational study for correlation between tumor mutation burden and immunotherapy efficacy of advanced non-small cell lung cancer with malignant pleural effusion

NCT ID: NCT04131231 Not yet recruiting - Breast Cancer Clinical Trials

Safety and Effectiveness of MPCD Therapy on the Treatment of Malignant Pleural Effusion

Start date: October 15, 2019
Phase: N/A
Study type: Interventional

This is a prospective, open-label , multicenter randomized controlled trial, with 248 cases in 50 centers planned for a period of 2 years. The aim of the study is to evaluate the safety and effectiveness of microparticles packaging chemotherapeutic drugs (MPCD) therapy on the treatment of malignant pleural effusion (MPE) in patients with advanced lung cancer or breast cancer.

NCT ID: NCT04074902 Not yet recruiting - Pleurodesis Clinical Trials

Role of Chest Sonography in Evaluation of Pleurodesis in Patients With Malignant Pleural Effusion

Start date: September 2019
Phase:
Study type: Observational

Thoracic ultrasonography easily detects the movement of the visceral pleura on the parietal pleura This sign is absent when pleurodesis is successful.

NCT ID: NCT03781908 Not yet recruiting - Clinical trials for Pleural Effusion, Malignant

Management of Malignant Pleural Effusion With Indwelling Pleural Catheter Versus Silver Nitrate Pleurodesis

Start date: January 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The primary goal of this study is to compare well-defined pleural effusion management success outcomes in patients with malignant or paramalignant pleural effusions who were treated with Indwelling pleural catheter insertion compared with those treated with siver nitrate pleurodesis. It is also to demonstrate the effectiveness of silver nitrate pleurodesis. It is also important to evaluate frequent adverse events of silver nitrate pleurodesis in patients with malignant pleural effusion